Stock of Edgewise Therapeutics, Inc. (EWTX) is falling around 10 percent on Tuesday morning despite the company announcing encouraging top-line results from its 12-week Phase 2 Part D CIRRUS-HCM trial, showing meaningful improvements in heart function without reductions in systolic performance.
The company's stock is currently trading at $31.69, down 10.00 percent or $3.52, over the previous close of $35.21 on the Nasdaq. It has traded between $12.15 and $40.76 in the past one year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.